| Literature DB >> 30621480 |
Hai-Zhen Zhu1, Jing Hou2, Yi Guo3, Xin Liu4, Fei-Long Jiang5, Guang-Peng Chen6, Xiu-Feng Pang7, Jian-Guo Sun6, Zheng-Tang Chen6.
Abstract
Lung cancer is still the most common cancer globally. Early screening remains the key to improve the prognosis of patients. There is currently a lack of specific and sensitive methods for early screening of lung cancer. In recent years, studies have found that microRNA plays an important role in the occurrence and development of lung cancer and become a biological target in the early diagnosis of lung cancer. In this study, lung cancer cells, subcutaneous xenografts of lung cancer in nude mice, and Lox-Stop-lox K-ras G12D transgenic mice were used as models. The transgenic mice displayed the dynamic processes from normal lung tissue to atypical hyperplasia, adenomas, carcinoma in situ and lung adenocarcinoma. It was found that miR-155 and somatostatin receptor 2 (SSTR2) were expressed in all the disease stages of transgenic mice. Through molecular beacon (MB) technology and nanotechnology, chitosan-molecular beacon (CS-MB) nanoparticles and targeted octreotide (OCT) were conjugated and synthesized. The octreotide-conjugated chitosan-molecular beacon nanoparticles (CS-MB-OCT) can specifically bind to SSTR2 expressed by the lung cancer cells to achieve the goal of identification of lung cancer cells and imaging miR-155 in vivo and in vitro. Fluorescence imaging at different disease stages of lung cancer in Lox-Stop-lox K-ras G12D transgenic mice was performed, and could dynamically monitor the occurrence and development of lung cancer by different fluorescence intensity ranges. The current research, in turn, provides new idea, new method, and new technology for the early screening of lung cancer.Entities:
Keywords: Lung cancer;microRNA-155;molecular beacon;chitosan nanoparticles;molecular imaging
Mesh:
Substances:
Year: 2018 PMID: 30621480 PMCID: PMC6327580 DOI: 10.1080/10717544.2018.1516003
Source DB: PubMed Journal: Drug Deliv ISSN: 1071-7544 Impact factor: 6.419
Figure 1.Schematic illustration of transfection of miR-155 MB into the cells via CS-MB-OCT nanoparticles for imaging of intracellular miRNA.
Figure 2.SSTR2 and miR-155 expression detection and animal model establishment. (a) SSTR2 expression by immunofluorescence. Scale bar = 50 μm. (b) HE staining at 4, 6, 8 and 12 weeks. (c) SSTR2 expression by immunohistochemistry (×400). (d) miR-155 expression in the subcutaneous xenografts (n = 6). (e) miR-155 expression in transgenic mice (n = 6). Data are presented as mean ± standard deviation (*p < .05).
Figure 3.Physicochemical characteristics of CS-MB-OCT nanoparticles. (a) The CS-MB, OCT and CS-MB-OCT absorption spectrum. (b) The mean size of CS-MB and CS-MB-OCT (n = 3). The data were displayed as mean ± standard deviation. (c) TEM images of CS-MB-OCT. Scale bar =100 nm.
Figure 4.Fluorescence imaging and identification of miR-155 in vitro. (a) Confocal microscopy imaging. Scale bar = 50 μm. (b) Fluorescence intensity of miR-155 was measured after transfection with CS-miR155 MB-COT, CS-miR155 MB or siPORT-miR155 MB (n = 3). (c, d) Graphs by flow cytometry analysis and transfection efficiency of the three cell lines transfected with CS-miR155 MB-COT, siPORT-miR-155 MB and CS-miR-155 MB (n = 3). (*p < .05, vs siPORT-miR-155 MB; *p < .05 vs CS-miR-155 MB).
Figure 6.Fluorescence imaging and identification of miR-155 of transgenic mice at different disease stages. (a) IVIS spectrum imaging system imaging after injection of CS-MB-OCT into the tail vein. (b) IVIS spectrum imaging system of the lungs after removal. (c) Fluorescence intensity was measured after injection (n = 6, *p < .05). (d) Confocal microscopy of different pathological changes after transfection with CS-MB-OCT. Scale bar = 25–100 μm.